The interaction between tumor and the immune system is still poorly understood. Significant clinical responses have been achieved in cancer patients treated with antibodies against th e CTLA4 and PD-1/PD-L1 checkpoints; however, only a small portion of patients responded to the therapies, indicating a need to explore additional co-inhibitory molecules for cancer treatment. B7-H3, a member of the B7 superfamily, was previously shown by us to inhibit T-cell activation and autoimmunity. In this study, we have analyzed the function of B7-H3 in tumor immunity. Expression of B7-H3 was found in multiple tumor lines, tumor-infiltrating dendritic cells, and macrophages. B7-H3-deficient mice or mice treated with an antagonistic antibody to B7-H3 showed reduced growth of multiple tumors, which depended on NK and CD8 + T cells. With a putative receptor expressed by cytotoxic lymphocytes, B7-H3 inhibited their activation, and its deficiency resulted in increased cytotoxic lymphocyte function in tumor-bearing mice. Combining blockades of B7-H3 and PD-1 resulted in further enhanced therapeutic control of late-stage tumors. Taken together, our results indicate that t h e B7-H3 checkpoint may serve as a novel target for immunotherapy against cancer.
Introduction
T-cell tolerance is controlled by a combinatorial costimulation signal. Whereas CD28 and ICOS (inducible T-cell co-stimulator) are important in T-cell activation or function, negative co-stimulation, or co-inhibition, maintains the threshold of T-cell activation [1, 2] . Increasing evidence indicates that these co-inhibitory molecules, such as PD-1 (programmed death 1) and its ligand PD-L1 (aka B7-H1, B7 homolog 1), are present in the tumor microenvironments and help tumor cells to evade immune destruction [3] . Blockade of PD-L1 alleviated suppression of tumor immunity mediated by myeloid dendritic cells (mDCs) through regulation of cytokine production [4] . Anti-CTLA4 and anti-PD-1 antibody treatments have shown clinical efficacy in cancer patients [5] [6] [7] , highlighting a new pathway for tumor immunotherapy [8] . However, not all patients or cancer models respond to these checkpoint inhibitors. For example, we previously found that anti-PD-L1 was not effective in promoting tumor regression in the B16 melanoma model [9] , suggesting that additional pathways ought to be studied to achieve optimal tumor immunity.
B7-H3 (CD276) is one of the B7 superfamily molecules [10, 11] . In mice, B7-H3 is constitutively expressed on professional antigen-presenting cells (APCs) and gets upregulated on DCs after activation with lipopolysaccharide (LPS) [12] . B7-H3 co-inhibitory function was described using a B7-H3-Ig fusion protein, where it decreased proliferation, and interleukin-2 (IL-2) and interferon-γ (IFN-γ) production by T cells activated with anti-CD3 [12, 13] . Moreover, B7-H3 gene deletion or blockade with an antibody enhanced experimental autoimmune encephalomyelitis [12, 13] . In humans, B7-H3 was first reported in DCs as a positive co-stimulator that enhanced IFN-γ production during T-cell activation [10] . However, more recently, a study showed potent inhibition of IFN-γ, IL-2, IL-10, and IL-13 production during T-cell activation [14] . So far the receptor for B7-H3 has not been identified.
In cancer patients, B7-H3 expression was previously identified as a poor prognostic factor. For example, B7-H3 expression in non-small cell lung cancer patient is associated with an advanced tumor stage, tumor size, and lymph node metastasis [15, 16] . In carcinomas, B7-H3 expression in tumors correlated with shorter survival time and higher cancer recurrence [17] . Although these and other studies implicate a role for B7-H3 in human cancers, the underlying mechanism of B7-H3 function in cancer has remained unclear.
In the current study, we have analyzed the role of B7-H3 in murine cancer models. We found that B7-H3 was expressed in the tumor microenvironment of mouse and human tumors. B7-H3 inhibition controlled tumor growth and anti-tumor immunity was dependent on CD8 + T cells and natural killer (NK) cells. Moreover, B7-H3 directly inhibited the activation of NK cells. Thus, B7-H3 serves as a critical negative regulator in tumor immunity and could in principle be targeted in cancer immunotherapy.
Results

Expression of B7-H3 and its receptor in human and murine tumors
As a first step to analyze the role of B7-H3 in cancer immunology, we determined the expression of B7-H3 in cancer patients. Analysis of The Cancer Genome Atlas (TCGA) data revealed that transcripts of B7-H3 were upregulated in multiple types of tumors in comparison with matched normal tissues (Supplementary information, Figure S1 ). We also tested the mRNA and protein levels of B7-H3 in biopsies from patients with hepatocellular carcinoma (HCC) or melanoma. In HCC patients, expression of B7-H3 on CD14 + HLA-DR hi macrophages, CD14 + HLA-DR low/− monocytic myeloid-derived suppressive cells, and mDCs was upregulated in the liver compared with the peripheral blood, whereas APCs in the tumor possessed even higher B7-H3 expression than in the normal liver or para-tumor areas (Supplementary information, Figure S2A ). Expression of B7-H3 was also detected on CD45 − cells by immunofluorescence and was higher in the tumor than in the normal liver ( Figure 1A ). We also determined B7-H3 expression in human melanoma cells lines obtained from resected tumors. Although B7-H3 mRNA expression was found at different levels in the melanoma cell lines and DCs cultured in vitro ( Figure  1B ), B7-H3 protein was similarly highly expressed on these cells ( Figure 1C ). More importantly, protein expression of B7-H3 was found on macrophages and DCs derived from human melanoma infiltrates ( Figure 1D ). The B7-H3 receptor has not been identified [13] but previous results have indicated the presence of a putative receptor on activated T cells. To assess the expression of B7-H3 receptor in HCC patients, we tested the binding of a human B7-H3-mouse IgG2a fusion protein to lymphocytes in the peripheral blood mononuclear cells, normal liver, para-tumor, and tumor. We observed increased expression of B7-H3 receptor on CD4 + and CD8 + T cells in the liver compared to that in the peripheral blood (Supplementary information, Figure S2B ). B7-H3 expression by tumor cells, tumor-infiltrating APCs, and B7-H3 receptor expression by lymphocytes strongly suggest their regulatory role in the tumor microenvironment.
To understand the functions of B7-H3 in murine tumors, we used an anti-B7-H3 antibody we previously generated [12] , to examine B7-H3 expression. Surprisingly, we found B7-H3 intracellularly in both the mouse E.G7 lymphoma and B16-F10 melanoma cells but not on their surface ( Figure 1E ). The expression of B7-H3 mRNA was also found in these cells, ruling out the possibility of cross-reactivity in the intracellular staining ( Figure 1F ). Interestingly, 7 days after inoculation in syngeneic mice, B7-H3 was highly expressed on the surface of both E.G7 and B16-F10 tumor cells ( Figure 1G ), suggesting its surface expression can be induced by the tumor microenvironment. MOPC 315 myeloma cells had both cell surface and intracellular B7-H3, whereas A20 lymphoma cells showed only its intracellular expression ( Figure 1E ). In addition to expression in the tumor cells, B7-H3 was also present on the surface of tumor-infiltrating macrophages and DCs in E.G7 and B16 models (Figure 1G) . To investigate the expression of B7-H3 receptor on mouse tumor-infiltrating lymphocytes (TILs), we tested the binding of mouse B7-H3-Ig fusion protein to cells isolated from tumors and spleens of E.G7-bearing mice. Both NK and CD8 + T cells from TILs and splenocytes (SPL) were strongly bound by mouse B7-H3-Ig protein.
In contrast, CD4 + T cells did not bind to B7-H3-Ig (Supplementary information, Figure S3A -S3B). Similar to E.G7 tumors, NK cells from B16-F10 melanoma also bound to B7-H3-Ig (Supplementary information, Figure  S3C ). These results suggest that B7-H3 might act on NK and CD8 + T cells.
B7-H3 inhibition suppresses tumor development
To investigate the role of B7-H3 in tumor development, B7-H3-deficient (KO) [13] and wild-type (WT) mice, both on C57BL/6 background, were injected subcutaneously with E.G7 cells, and tumor growth was evaluated for 3 weeks. Lack of B7-H3 significantly reduced the growth of E.G7 cells to about 50% when compared to WT mice ( Figure 2A ). These data suggest that B7-H3 inhibition could enhance anti-tumor immunity. We therefore examined the therapeutic effects of B7-H3 blockade in multiple transplanted hematopoietic tumors using anti-B7-H3 blocking antibody. Syngeneic mice receiving live tumor cells on day 1 (intravenously for A20 and subcutaneously for E.G7 and MOPC315 cells) were treated with anti-B7-H3 antibody on day 3 followed by 10 injections every other day. Anti-B7-H3 treatment significantly reduced tumor growth in E.G7-or MOPC 315-bearing mice and prolonged the survival in > 30% of A20-bearing mice by at least 1 more month ( Figure 2B-2D ). Interestingly, anti-B7-H3-treated B7-H3 KO mice had similar tumor growth as the B7-H3 KO mice ( Figure  2A ), indicating that B7-H3 expression by host immune cells is more important and also suggesting that the antibody did not deplete tumor cells via antibody-dependent cellular cytotoxicity (ADCC).
Since B7-H3 expression was observed in human and murine melanoma, we also evaluated B16-F10 melanoma development in B7-H3 KO mice. The tumors cells were injected intravenously into the mice to promote melanoma colony growth in the lungs [18] . Fourteen days after the challenge, B7-H3 KO mice exhibited only 1/3 to 1/10 of the colonies found in WT mice ( Figure 2E) . Likewise, treatment with anti-B7-H3 blocking antibodies as a therapeutic regimen reduced B16-F10 growth in the lungs; the tumor foci formed in mice treated with anti-B7-H3 were smaller in size when compared to those treated with rat IgG ( Figure 2F ). Taken together, our results with hematopoietic and non-hematopoietic tumor models indicate the important role of B7-H3 in the development of multiple tumors from different tissue origins.
NK and CD8 + T cells are required in B7-H3-mediated tumor immunity
To understand the functional mechanisms of B7-H3 in tumor development, we examined tumor-infiltrating immune cells as well as SPL from B7-H3 KO or WT mice harboring the E.G7 tumor. CD11b + Gr1
+ cells, described as myeloid-derived suppressor cells [19] , were reduced in the spleen and tumor of B7-H3 KO mice or mice treated with anti-B7-H3 when compared to the control groups (Supplementary information, Figure S4A -S4B). However, the population of regulatory T cells, also Ki-67 positive, did not show differences in the spleen and tumors of B7-H3 KO and WT mice, respectively (Supplementary information, Figure S4C-S4D) .
To determine the functional target cell of B7-H3 in our tumor models, CD4 + , CD8 + , or NK cells were depleted using selective mAbs before challenging with the E.G7 tumor. Interestingly, depletion of NK cells or CD8 + T cells greatly prevented the control of tumor growth seen in B7-H3 KO mice. Double depletion of NK and CD8 + T cells further abrogated the suppression of tumor growth in B7-H3 KO mice. In contrast, depletion of CD4 + T cells did not influence the tumor growth in B7-H3 KO mice ( Figure 3A-3B) . We also confirmed that depletion of NK cells or CD8 + T cells reduced the anti-tumor effect of anti-B7-H3 Ab treatment (Supplementary information, Figure S5A ). Moreover, mice depleted of both CD8 + T and NK cells developed larger tumors than mice with single depletion. Similarly, in the B16-F10 melanoma model, depletion of NK cells in B7-H3 KO mice increased the numbers of tumor foci ( Figure 3C ). However, depletion of CD8 + T cells did not have any effect on lung metastasis in B7-H3 KO mice, consistent with the poor ability of B16-F10 to induce CD8 + T cell responses [20] . Interestingly, when the B16-OVA line was used, CD8 + T cells became important in B7-H3 inhibition-mediated tumor reduction ( Figure 3D ). Taken together, these results indicate that anti-tumor immunity generated by B7-H3 inhibition is dependent on CD8 + T cells and especially NK cells.
B7-H3 regulates anti-tumor CD8
+ T cells When TILs were phenotypically evaluated, the proportions of CD4 + and CD8 + T cells did not change in the tumor of B7-H3 KO mice ( Figure 4A) . Since E.G7 tumors express ovalbumin (OVA) antigen, we evaluated OVA-reactive CD8 + T cells from TILs. SIINFEKL tetramer positive cells were doubled in tumors from B7-H3 KO mice compared to WT mice ( Figure 4B ). Further analysis revealed that these CD8 + T cells expressed increased levels of IFN-γ and Granzyme B. Percentage of IFN-γ + and Granzyme B + CD4 + TILs was also increased in B7-H3-deficient mice ( Figure 4C ). Interestingly, depletion of NK cells substantially reduced Granzyme B-expressing CD8 + T cells in the TILs, while depletion of CD8 + T cells reduced expression of Granzyme B by tumor-infiltrating NK cells in B7-H3-deficient mice (Figure 4D) . Also, CD8
+ T cells and NK cells in the tumor tissues of B7-H3 KO mice had reduced PD-1 expression when compared to cells in WT mice ( Figure 4E ). We also tested whether B7-H3 inhibits CD8 + T-cell activation in in vitro co-culture of DCs and CD8 + T cells. Splenic DCs from WT or B7-H3 KO mice were isolated and co-cultured with CFSE-labeled OVA-specific CD8 + T cells (OT-I) in vitro for 3 days and proliferation was evaluated by dilution of CFSE intensity. DCs from B7-H3 KO mice induced increased proliferation of OT-I T cells compared with DCs from WT mice (Supplementary information, Figure S4E ). More importantly, OT-I T cells stimulated by DCs from B7-H3 KO mice displayed remarkably higher expression of Granzyme B and IFN-γ compared with those stimulated by DCs from WT mice (Supplementary information, Figure S4E ). Thus, B7-H3 inhibition might enhance the number and cytolytic function of tumor antigen-specific CD8 + T cells.
B7-H3 regulates NK-cell function
To understand the role of B7-H3 in regulating NKcell-mediated tumor protection, we analyzed the quantity and function of NK cells in E.G7-or B16.F10-tumors developing in WT or B7-H3-deficient host mice. The percentage and absolute number of NK cells were increased in the B7-H3 KO mice (Supplementary information, Figure S5B-S5C) . Furthermore, B7-H3 KO mice showed a substantial increase in Granzyme B-producing NK cells in TILs from both E.G7-and B16.F10-bearing mice ( Figure 5A -5B). CD69, an NK activation marker, was upregulated on NK cells in the spleen and tumors from Figure 5C and Supplementary information, Figure S5D ). To determine regulation of the NK killing function by B7-H3, NK cells were isolated from spleen and TILs of E.G7-bearing mice and the killing of E.G7 cells tested in vitro by detection of cleaved levels of caspase-3 [21] . NK cells from B7-H3 KO mice were more efficient in tumor killing when compared with those from control mice (two-fold increase) ( Figure 5E ). These results indicate that B7-H3 controls NK-cell activation in the tumor microenvironment. Since B7-H3 is expressed by DCs, we tested whether DCs derived from B7-H3 KO mice could induce NK-cell activation more effectively in vitro. DCs isolated from WT or B7-H3 KO mice were stimulated with LPS for 18 h before being co-cultured with NK cells. After overnight activation with the DCs, killing of YAC-1 cells by NK cells was evaluated using the Caspase3-based assay. DCs from B7-H3 KO mice induced a stronger NK-mediated killing activity than WT DCs ( Figure 5D ) thus supporting a role for B7-H3 in inhibition of NK-cell activation.
B7-H3 KO mice (
To investigate the potential effect of the B7-H3 molecule on human NK cells, their degranulation was tested in an in vitro ADCC assay. Briefly, the fluorescence intensity of the CD107a molecule on the plasma membrane of NK cells (a marker for NK-cell degranulation) was assessed by confocal microscopy of NK cells placed on lipid bilayers coated with antibodies against CD16 to mediate ADCC, in the presence or absence of B7-H3-Ig. When NK cells were incubated on bilayers carrying anti-CD16 alone, a strong CD107a signal accumulated at the center of the synapse, which was indicated by the central clustering of anti-CD16 molecules on the lipid bilayer ( Figure 5F ). However, when NK cells were incubated on bilayer containing anti-CD16 in combination with B7-H3-Ig, the mean fluorescence intensity of CD107a on the PM of NK cells was decreased ( Figure 5F ). Further analysis of CD16 clusters on the lipid bilayer revealed that B7-H3-Ig significantly decreased the accumulation of anti-CD16 molecules on the lipid bilayer ( Figure 5F ). Similar results were observed on a lipid bilayer containing NKG2D and 2B4 antibodies to induce natural cytotoxicity, with and without B7-H3 ( Figure 5G ). NK cells placed on control lipid bilayers loaded with IgG in the presence or absence of B7-H3 had no detectable CD107a fluorescence (Supplementary information, Figure S6 ).
Combination therapy with anti-B7-H3 and anti-PD-1
Based on our data, it seemed that B7-H3 should be a good target for immunotherapy against lymphoma and melanoma because blocking of B7-H3 with a specific antibody induced anti-tumor immunity. Since B7-H3 and PD-L1 were expressed in the E.G7 model and in human cancers, we decided to test the blockade of B7-H3 in the context of a PD-1 blockade, which has already shown significant anti-tumor effects in human cancers [6, 22] . Groups of C57BL/6 mice were subcutaneously transplanted with 1 × 10 6 E.G7 cells and treated with intraperitoneal injection of control, anti-B7-H3 antibody, anti-PD-1 antibody, or anti-B7-H3 plus anti-PD-1 antibodies one day 7, 10, 13, 16, and 19, respectively. Although treatment with a single antibody against B7-H3 or PD-1 exhibited an anti-tumor effect, the combined anti-B7-H3 and anti-PD-1 antibody treatment further reduced tumor volume and tumor weight ( Figure 6A ). In contrast, earlier treatment with a combinational blockade starting from day 3 did not show synergistic effects, as the single antibody treatment was already effective ( Figure 6B) . Therefore, combination therapy with anti-B7-H3 and anti-PD-1 can generate powerful anti-tumor immunity, especially in late-stage cancers.
Discussion
Immunotherapy has arisen as a new type of treatment for cancer. Considerable success has been achieved in multiple cancers, including melanoma, by use of checkpoint inhibitors anti-CTLA4 and/or anti-PD-1/PD-L1 [4, 6] . These exciting advancements in the clinic have implicated other co-inhibitory molecules as potential targets for cancers. Here, we report the function of B7-H3 in several transplantation tumor models, highlighting this molecule as a potential target for cancer immunotherapy.
Although B7-H3 was originally described as a positive regulator of T cells in humans [10] , growing evidence has indicted that it may indeed be a negative regulator. Lack or inhibition of B7-H3 resulted in enhanced autoimmunity [12, 13] . Recently, it was also found that B7-H3 also potently inhibited human T-cell activation [14] . In this paper, we showed that both murine and human B7-H3 inhibited NK-cell activation. The reason underlying the different results is unclear, in part because the receptor for B7-H3 has not been identified. Although it has been suggested that TLT2 is a receptor for B7-H3 [23] , it has not been confirmed by others and us in another study [14] . Thus, it will be important in the near future to identify the B7-H3 receptor in order to fully determine the diverse functions of B7-H3, and also to detail the inhibitory signaling pathway. The variable function of B7-H3 may be caused by differential glycosylation, which has been reported in B7-H3 molecules expressed in oral squamous cell carcinoma [24] . This suggests that glycosylation of B7-H3 in tumors regulates B7-H3's immune function. The anti-B7-H3 blockade may be happening on APCs infiltrating the tumor cells. So far it is unknown 6 E.G7 cells and given an intra-peritoneal injection of control IgG, anti-B7-H3 (100 µg), anti-PD-1 (100 µg), or anti-B7-H3 plus anti-PD-1 antibody starting on day 3 (B) or 7 (A) and every 3 days for a period of 3 weeks . Tumor volume was measured every other day. Data are a representative of at least two separate experiments. *P ≤ 0.05, **P ≤ 0.01.
whether B7-H3 functions via the infiltrating DC, macrophages, and/or the tumor cells. In the E.G7 model at least, the function of B7-H3 appears to be most important in the non-tumor cells, most likely the tumor-infiltrating DCs and macrophages. Indeed, we found that DCs lacking B7-H3 are more potent in the induction of NK and CD8 + T-cell function. However, it is likely that in another context, tumor expression of B7-H3 may also be important. Our anti-B7-H3 did not have depletion effect on DCs and macrophages, suggesting that it modulates immune cell function instead.
B7-H3 expression has been associated with poor prognosis in multiple cancers [16, 17, [25] [26] [27] [28] . In this study, we found that lack of B7-H3 suppressed the development of multiple cancers. Moreover, anti-B7-H3 had potent therapeutic effects in multiple murine models. Interestingly, we found that the function of B7-H3 was dependent on NK cells and CD8 + T cells. Although B7-H3 also negatively regulated CD8 + T-cell activation, B7-H3 function in the B16-F10 model was primarily mediated by NK cells indicating that B7-H3 function may vary depending on the tumor origins. B7-H3 inhibits both mouse and human NK-cell activation, in accord with previous reports which described B7-H3 binding to NK cells [29] . However, although both WT and KO groups of mice treated with anti-NK antibody had more tumor colonies than mice treated with control antibody, the NK-depleted KO mice did not develop as many colonies as the WT mice treated with anti-NK antibodies.
We suggest this could be due to incomplete depletion of NK cells, or because of compensation by CD8 + T cells. Indeed, double depletion of NK and CD8 + T cells resulted in even greater tumor growth (Figure 3) . In contrast to the B7-H3 receptor, PD-1 is not highly expressed by NK cells and previously we did not find a therapeutic effect of anti-PD-L1 in the B16-F10 model [9] . This suggests a separation of labor such that B7-H3 co-inhibits NK cells while PD-1 primarily acts on CD8 + T cells. This may underscore the synergistic effects of B7-H3 and PD-1 antibodies in late stage cancer. Overall, our data strongly support for a role of B7-H3 in tumor immunity and suggest the potential value of targeting the B7-H3 checkpoint alone or together with PD-1 to serve as a new immunotherapy against cancers.
Materials and Methods
Patients and specimens
Fresh specimens and matched blood of HCC patients were obtained from the China-Japan Friendship Hospital. For isolation of tissue-infiltrating leukocytes, fresh normal liver, paratumor, and tumor specimens from HCC patients were digested in RPMI-1640 medium supplemented with 0.5 mg/ml Collagenase Type IV (Gibco), 10% FBS plus 10 U/ml DNase I, minced into small pieces manually, and then transferred to 70 µm cell strainers (BD) and mechanically separated using the plunger of a 5-ml syringe. The cells passing through the cell strainer were collected and subjected to Ficoll-Hypaque gradient centrifugation. After centrifugation, mononuclear cells were recovered and stored at −80 ºC until flow cytometry analysis or immediately used for experiments. For immunofluorescence staining, all samples were fixed in formalin solution and embedded in paraffin. Sections were dewaxed in xylene, dehydrated in ethanol, and incubated in 3% H 2 O 2 for 15 min to destroy the activity of endogenous peroxidase. After blocking with 10% normal donkey serum, each slide was incubated with the primary antibodies at 4 ºC overnight. AffiniPure F(ab′) 2 Fragment donkey anti-rabbit/mouse/goat immunoglobulin was chosen as the second antibody. All experimental protocols were approved by the institutional review committee.
Expression and purification of human B7-H3-mIgG2a Fc fusion protein
Using an expression vector pcDNA3.4 (ThermoFisher Scientific), human B7-H3-mIgG2a Fc fusion protein, which contains amino acids Leu29-Pro245 of the B7-H3 extracellular domain (NCBI: NP_079516) and amino acids Pro99-Lys330 of the mouse IgG2a Fc fragment (GeBank: CAA24178.1), was transfected into FreeStyle 293-F cells (ThermoFisher Scientific). Cell culture supernatants were collected at 96h post-transfection. A protein A affinity column was pre-equilibrated with 20 mM Na 2 HPO 4 buffer with 0.15 M NaCl, pH 7.2. Bound B7-H3-mIgG2a fusion protein was eluted with 0.1 M Glycine (pH 2.7), and dialyzed in PBS buffer (pH 7.2).
Evaluation of B7-H3 expression
Melanoma cell lines, 2406, 2417, 2423, 2437, and 2442 were derived from melanoma tissue resected during surgery using clinical and laboratory protocols approved by the MD Anderson Cancer Center Institutional Review Board. Cell lines were grown and mRNA isolation was performed as previously reported [18] . RT-PCR was done using a Cyber green based kit (Bio-Rad, CA, USA) with the following primers: Forward 5′-AGCACTGTGGTTCT-GCC TCACA -3′ Reverse 5′-CACCAGCTGTTTGGTATCTGT-CAG-3′. Surface expression of B7-H3 was evaluated using 110 mAb reported previously [12] followed by a biotinylated anti-Rat antibody and streptavidin Alexafluor 488 (Life Technologies, CA, USA). For the B7-H3-Ig binding assay, CD4 + , CD8 + , and NK cells were isolated from TILs or SPL of E.G7-bearing mice, and the B7-H3-Ig-binding assay determined as previously reported [11] . Mice C57BL/6 and Balb/c mice were purchased from the Jackson Laboratory or NCI facility. B7-H3-deficient mice (C57BL/6 background) or co-housing B6 mice were bred at MD Anderson SPF facility. Mice were used at 6-10 weeks of age. The animal protocol (05-05-04233) was approved by the IACUC of MD Anderson.
Tumor experiments C57BL/6 mice or B7-H3 KO mice of the same background were injected intravenously with 1 × 10 5 B16-F10 cells to promote melanoma growth in the lung, and 2 weeks later the mice were euthanized to evaluate tumor foci numbers in the lungs. Skin lymphomas were grown in C57BL/6 or B7-H3 KO mice by injecting 1 × 10 6 E.G7 cells sub-cutaneously, and tumor size was monitored using a caliper. Similarly, Balb/c mice were intravenously injected with 1 × 10 6 A20 lymphoma or subcutaneously with 1 × 10 6 MOPC 315 myeloma cells. Survival was evaluated in mice injected with A20 and tumor growth in MOPC 315 injected mice. Mice were sacrificed when the tumor diameters reached 20 mm. B7-H3 blockade was performed by injecting intraperitoneally 100 µg of anti-B7-H3 mAb (clone 110) or control rat IgG on the indicated days. A20-and MOPC 315-bearing mice received a total of 10 injections of antibodies and B16-F10-bearing mice 5 injections. Survival was monitored for 70 days after tumor challenge. Tumor volume was calculated by the ellipse formula, length/2 × width/2 × π. Blocking antibodies for B7-H3 (clone 110) and PD-1 (clone J43) were produced in high quantities by BioXcell (NH, USA).
Antibody-mediated depletion
Monoclonal anti-CD4 (GK1.5) and anti-CD8 (523.7) antibodies (Abs) were purchased from BioXcell (NH, USA) and NK depletion Ab-asialo-GM1 (ASGM1) from WAKO Pure Chemicals (Osaka, Japan). To deplete CD4, CD8, or NK cells, 100 µg of anti-CD4 or anti-CD8 mAb, or 50 µg ASGM1 antibodies were injected intraperitoneally twice (on days 3 and 1) into the mice. On day 0, mice were challenged with 1 × 10 6 live E.G7 (subcutaneously injected), 1 × 10 5 B16.F10 cells (intravenously injected), or 1 × 10 5 B16.OVA (intravenous injection).
Isolation of tumor-infiltrating cells
Tumor-infiltrating cells from lungs were isolated using a previously described protocol [18] . Briefly, tumors were digested with 1 mg/ml collagenase D for 1 h at 37 °C, and the lymphocyte faction was isolated after gradient-centrifugation of the cell suspension. Lymphocyte fractions were counted and used for flow cytometry analysis.
Antibodies and flow cytometry
The following fluorescent dye-conjugated anti-human antibodies were used for staining: anti-CD45 (HI30), anti-HLA-DR (L243), anti-CD11c (3.9), anti-B7-H3 (DCN.70), Streptavidin-BV421, anti-CD3 (OKT3), and anti-CD56 (HCD56) (Biolegend, CA, USA); anti-CD14 (MP9), anti-CD123 (7G3), and anti-CD8 (SK1) (BD biosciences, CA, USA). Antibodies to mouse proteins were as follows: anti-CD4 (GK1.5), anti-CD8 (53-6.7), anti-CD11b (M1/70), anti-CD69 (H1.2F3), anti-PD-1 (J43), anti-Gr1 (1A8), anti-NK1.1
